Abstract
Background Clinical intracranial vessel wall imaging (VWI) requires high spatial resolution leading to long scan times and artifacts.
Purpose To accelerate standard-of-care (SOC) 3D T1-weighted variable-flip-angle turbo-spin-echo (VFA-TSE) sequence with parallel imaging (Generalized Autocalibrating Partially Parallel Acquisitions, GRAPPA) using compressed sensing (CS) or Controlled Aliasing in Parallel Imaging Results in Higher Acceleration (CAIPIRINHA, CAIPI) with either standard or large field-of-view (FOV) configurations to reduce scan time, artifacts and accommodate head sizes.
Study Type Prospective study.
Subjects Ten healthy volunteers.
Field Strength/Sequence 3 Telsa, 20-channel head coil, T1-weighted VFA-TSE
Assessment Accelerated sequences were compared to SOC GRAPPA (R=2), including standard FOV CAIPI (SFCAIPI, R=4), CS (SFCS7, R=7), and large FOV CS (LFCS7, R=7; LFCS10, R=10). Four neuroradiologists rated image quality (IQ) and signal-to-noise ratio (SNR) using a 4-point Likert scale. Scores of 3–4 were categorized as clinically interpretable. Lumen and wall diameters were measured.
Statistical Analysis Descriptive statistics are reported. McNemar’s test compared proportions of IQ- and SNR-based clinically interpretable scans between relevant sequences of interest. Inter- and intra-rater reliabilities were calculated with Fleiss Kappa and weighted Cohen’s Kappa, respectively. Lumen and wall diameters of the CS- and CAIPI-accelerated sequences were compared to SOC using paired t-tests.
Results SFCAIPI showed the lowest mean IQ and SNR scores. SFCS7 showed no significant difference in the proportion of IQ-based clinically interpretable scans compared to SFGRAPPA. When testing FOV, LFCS7 (35/40 scans; time of acquisition (TA)=3:45) showed a significantly higher proportion of IQ-based clinically interpretable scans compared to SFCS7 (27/40, p=0.03; TA=6:37). Upon increasing acceleration (R=10), there was no difference in the proportion of IQ-based clinically interpretable scans between LFCS7 and LFCS10 (36/40, p=0.65). Large FOV eliminated aliasing artifacts compared standard FOV (aliasing in 7 of 10 subjects). LFCS10 (TA=4:55) achieved a 50.6% reduction in TA relative to SFGRAPPA (TA=9:57).
Conclusion Large FOV CS VWI sequence with 10x acceleration achieved a 50.6% reduction in scan time while delivering image quality comparable to SOC standard FOV GRAPPA.
Competing Interest Statement
Disclosures: Manuel Taso and Robert Sellers are employed by Siemens Medical Solutions, USA
Funding Statement
Grant Support: Jae W Song is supported by American Heart Association Career Development Award (938082) and Institute of Translational Medicine and Therapeutics; Zhaoyang Fan is supported by R01HL147355; Chengcheng Zhu is supported by R01HL162743.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the University of Pennsylvania provided ethical approval for this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Grant Support: JWS is supported by American Heart Association Career Development Award (938082) and Institute of Translational Medicine and Therapeutics; ZF is supported by R01HL147355; CZ is supported by R01HL162743.
Disclosures: MT and RS are employed by Siemens Medical Solutions, USA
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
